Magnus Åstrand

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 13

Top Topics

Induced Pluripotent Stem Cells

Placebo Controlled

Coronary Artery Disease

Top Venues

Journal of the American Heart Association

British journal of clinical pharmacology

Clinical pharmacology and therapeutics

Journal of the American Society of Nephrology : JASN

This page only lists publications with an associated author ORCID identifier.

Publications

Dimitris Kardassis, Ann-Charlotte Egnell, Magnus Åstrand, Samuel J Daniels, Carl Whatling, Ola Fjellström, Anders Gabrielsen
Safety, Tolerability, and Pharmacodynamics of AZD3366 (Optimized Human CD39L3 Apyrase) Alone and in Combination With Ticagrelor and Acetylsalicylic Acid: A Phase 1, Randomized, Placebo-Controlled Study. Journal of the American Heart Association 13 (11) (2024)
Kathleen Connolly, Richard T George, Sami Omar, Elin Matsson, Magnus Åstrand, Magnus Althage, Daniel Pettersen, Esha Mohamed, Kelly Fang, Joao Augusto Costa Lima, Mirjana Kujacic, Helena Ödesjö, Michelle Turton, Petra Johannesson, Anders Gabrielsen, Marcin Ufnal
Novel Relaxin Receptor RXFP1 Agonist AZD3427 in the Treatment of Heart Failure: A Phase 1a/b, First-in-Human, Randomized, Single-Blind, Placebo-Controlled Study. Journal of the American Heart Association 13 (15) (2024)
Kathleen Connolly, Richard T George, Sami Omar, Elin Matsson, Magnus Åstrand, Magnus Althage, Daniel Pettersen, Esha Mohamed, Kelly Fang, Joao Augusto Costa Lima, Mirjana Kujacic, Helena Ödesjö, Michelle Turton, Petra Johannesson, Anders Gabrielsen, Marcin Ufnal
Novel Relaxin Receptor RXFP1 Agonist AZD3427 in the Treatment of Heart Failure: A Phase 1a/b, First-in-Human, Randomized, Single-Blind, Placebo-Controlled Study. Journal of the American Heart Association (2024)
Dimitris Kardassis, Ann-Charlotte Egnell, Magnus Åstrand, Samuel J Daniels, Carl Whatling, Ola Fjellström, Anders Gabrielsen
Safety, Tolerability, and Pharmacodynamics of AZD3366 (Optimized Human CD39L3 Apyrase) Alone and in Combination With Ticagrelor and Acetylsalicylic Acid: A Phase 1, Randomized, Placebo-Controlled Study. Journal of the American Heart Association 13 (11) (2024)
Dimitris Kardassis, Ann-Charlotte Egnell, Magnus Åstrand, Samuel J Daniels, Carl Whatling, Ola Fjellström, Anders Gabrielsen
Safety, Tolerability, and Pharmacodynamics of AZD3366 (Optimized Human CD39L3 Apyrase) Alone and in Combination With Ticagrelor and Acetylsalicylic Acid: A Phase 1, Randomized, Placebo-Controlled Study. Journal of the American Heart Association 13 (11) (2024)
Anne-Kristina Mercier, Sebastian Ueckert, Mikael Sunnåker, Bengt Hamrén, Philip Ambery, Peter J Greasley, Magnus Åstrand
From Plan to Pivot: How Model-Informed Drug Development Shaped the Dose Strategy of the Zibotentan/Dapagliflozin ZENITH Trials. Clinical pharmacology and therapeutics 116 (3) (2024)
Dimitris Kardassis, Ann-Charlotte Egnell, Magnus Åstrand, Samuel J Daniels, Carl Whatling, Ola Fjellström, Anders Gabrielsen
Safety, Tolerability, and Pharmacodynamics of AZD3366 (Optimized Human CD39L3 Apyrase) Alone and in Combination With Ticagrelor and Acetylsalicylic Acid: A Phase 1, Randomized, Placebo-Controlled Study. Journal of the American Heart Association (2024)
Dimitris Kardassis, Ann-Charlotte Egnell, Magnus Åstrand, Samuel J Daniels, Carl Whatling, Ola Fjellström, Anders Gabrielsen
Safety, Tolerability, and Pharmacodynamics of AZD3366 (Optimized Human CD39L3 Apyrase) Alone and in Combination With Ticagrelor and Acetylsalicylic Acid: A Phase 1, Randomized, Placebo-Controlled Study. Journal of the American Heart Association 13 (11) (2024)
J David Smeijer, Victor S Wasehuus, Neeraj Dhaun, Jose Luis Gorriz Teruel, Maria José Soler, Magnus Åstrand, Anne-Kristina Mercier, Peter J Greasley, Philip Ambery, Hiddo J Lambers Heerspink
Effects of Zibotentan Alone and in Combination with Dapagliflozin on Fluid Retention in Patients with CKD. Journal of the American Society of Nephrology : JASN (2024)
Dimitris Kardassis, Ann-Charlotte Egnell, Magnus Åstrand, Samuel J Daniels, Carl Whatling, Ola Fjellström, Anders Gabrielsen
Safety, Tolerability, and Pharmacodynamics of AZD3366 (Optimized Human CD39L3 Apyrase) Alone and in Combination With Ticagrelor and Acetylsalicylic Acid: A Phase 1, Randomized, Placebo-Controlled Study. Journal of the American Heart Association 13 (11) (2024)
Anne-Kristina Mercier, Sebastian Ueckert, Mikael Sunnåker, Bengt Hamrén, Philip Ambery, Peter J Greasley, Magnus Åstrand
From Plan to Pivot: How Model-Informed Drug Development Shaped the Dose Strategy of the Zibotentan/Dapagliflozin ZENITH Trials. Clinical pharmacology and therapeutics (2024)
Muhammad Waqas Sadiq, Hongtao Yu, Magnus Åstrand, Ian C Scott, Adam Williams, Lisa Hewitt, Nicholas White, Helen Killick, Monica Gavala, E Suzanne Cohen, Fred Reid, Chris Kell, Hitesh Pandya, Eulalia Jimenez
Population pharmacokinetic/target engagement modelling of tozorakimab in healthy volunteers and patients with chronic obstructive pulmonary disease. British journal of clinical pharmacology (2024)
Magnus Åstrand, Carl Amilon, Daniel Röshammar, Anders Himmelmann, Dominick J Angiolillo, Robert F Storey, Paul A Gurbel, Marc P Bonaca, Bengt Hamrén
Pharmacokinetic-pharmacodynamic modelling of platelet response to ticagrelor in stable coronary artery disease and prior myocardial infarction patients. British journal of clinical pharmacology 85 (2) (2018)